VALLON PHARMACEUTICALS INC (VLON) Stock Fundamental Analysis

NASDAQ:VLON • US92023M1018

0.4 USD
-0.06 (-13.04%)
At close: Apr 21, 2023
0.3901 USD
-0.01 (-2.48%)
After Hours: 4/21/2023, 8:04:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

VLON gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. VLON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VLON is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VLON had negative earnings in the past year.
  • In the past year VLON has reported a negative cash flow from operations.
VLON Yearly Net Income VS EBIT VS OCF VS FCFVLON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -2M -4M -6M -8M

1.2 Ratios

  • The profitability ratios for VLON are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VLON Yearly ROA, ROE, ROICVLON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VLON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VLON Yearly Profit, Operating, Gross MarginsVLON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, VLON has more shares outstanding
  • VLON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VLON Yearly Shares OutstandingVLON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M
VLON Yearly Total Debt VS Total AssetsVLON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2M 4M 6M 8M

2.2 Solvency

  • VLON has an Altman-Z score of -12.80. This is a bad value and indicates that VLON is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VLON (-12.80) is worse than 82.65% of its industry peers.
  • There is no outstanding debt for VLON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.8
ROIC/WACCN/A
WACCN/A
VLON Yearly LT Debt VS Equity VS FCFVLON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 5M -5M

2.3 Liquidity

  • VLON has a Current Ratio of 2.29. This indicates that VLON is financially healthy and has no problem in meeting its short term obligations.
  • VLON has a Current ratio of 2.29. This is in the lower half of the industry: VLON underperforms 62.56% of its industry peers.
  • VLON has a Quick Ratio of 2.29. This indicates that VLON is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.29, VLON is in line with its industry, outperforming 43.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.29
VLON Yearly Current Assets VS Current LiabilitesVLON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.46% over the past year.
EPS 1Y (TTM)44.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VLON Yearly Revenue VS EstimatesVLON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 20K 40K 60K 80K
VLON Yearly EPS VS EstimatesVLON Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • VLON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLON Price Earnings VS Forward Price EarningsVLON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLON Per share dataVLON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VLON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VALLON PHARMACEUTICALS INC

NASDAQ:VLON (4/21/2023, 8:04:53 PM)

After market: 0.3901 -0.01 (-2.48%)

0.4

-0.06 (-13.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13
Earnings (Next)05-08
Inst Owners0.48%
Inst Owner Change-38.03%
Ins Owners8.38%
Ins Owner Change0%
Market Cap5.39M
Revenue(TTM)N/A
Net Income(TTM)-7.02M
Analysts82.86
Price Target12.24 (2960%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.29
Altman-Z -12.8
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.16%
OCF growth 3YN/A
OCF growth 5YN/A

VALLON PHARMACEUTICALS INC / VLON FAQ

What is the fundamental rating for VLON stock?

ChartMill assigns a fundamental rating of 1 / 10 to VLON.


What is the valuation status for VLON stock?

ChartMill assigns a valuation rating of 1 / 10 to VALLON PHARMACEUTICALS INC (VLON). This can be considered as Overvalued.


Can you provide the profitability details for VALLON PHARMACEUTICALS INC?

VALLON PHARMACEUTICALS INC (VLON) has a profitability rating of 0 / 10.